Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04527991
Title Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Immunomedics, Inc.
Indications

transitional cell carcinoma

Therapies

Paclitaxel

Docetaxel

Vinflunine

Sacituzumab govitecan-hziy

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.